the epidemic PCR-ribo type 001. In particular, the identity between the 2 PCR ribotypes was 100% for the HMW proteins and 77% for the LMW proteins.

This study provides convincing evidence that the S-layer is well conserved in *C. difficile* PCR-ribo type 027 strains and has high identity with the slpA of the epidemic PCR-ribo type 001. Because *C. difficile* PCR-ribo types 027 and 001 are the most frequently isolated strains from severe CDIs across both North America and Europe (9,10), the result obtained suggests that the S-layer of these virulent strains presents peculiar and common characteristics that could be an advantage for these bacteria during the infection process.

**Acknowledgments**

We thank the following participants of the 2005 European Prospective Study on *Clostridium difficile*: M. Delmé, D. Drudy, and E. Kuijper for providing strains AI13, AI16, AI18, DI12, and GI17; E. Kuijper for providing strain LUMC46; and T. Louie for providing strains M43 and A422. We also thank Tonino Sofia for editing the manuscript.

This work was partially supported by the European Community project “The Physiological Basis of Hypervirulence in *Clostridium difficile*: A Prerequisite for Effective Infection Control”—HEALTH-F3-2008-223585.

**Patrizia Spigaglia,**

**Fabrizio Barbanti,**

and **Paola Mastrantonio**

Author affiliations: Istituto Superiore di Sanità, Rome, Italy

DOI: 10.3201/eid1702.100355

**References**

1. O’Connor JR, Johnson S, Gerding DN. *Clostridium difficile* infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology. 2009;136:1913–24. DOI: 10.1053/j.gastro.2009.02.073

2. Calabi E, Calabi F, Phillips AD, Fairweather NF. Binding of *Clostridium difficile* surface layer proteins to gastrointestinal tissues. Infect Immun. 2002;70:5770–8. DOI: 10.1128/IAI.70.10.5770-5778.2002

3. Sára M, Sleytr UB. S-layer proteins. J Bacteriol. 2000;182:859–68. DOI: 10.1128/ JB.182.4.859-868.2000

4. Pantos A, Cerquetti M, Viti F, Ortisi G, Mastrantonio P. Immunoblot analysis of surface layer proteins from *Clostridium difficile* induce inflammatory and regulatory cytokines in human monocytes and dendritic cells. Microbes Infect. 2006;8:2640–6. DOI: 10.1016/j.micinf.2006.07.009

5. Ausiello CM, Cerquetti M, Fedele G, Spenzieri F, Palazzo R, Nasso M, et al. Comparative genome and phenotypic analysis of the gene for surface layer protein, slpA, from 14 PCR ribotypes of *Clostridium difficile*. J Med Microbiol. 2009;58:46204–0

6. Ejdihn DN, Ryan AW, Doyle RM, Walsh JB, Kelleher D. Sequence and phylogenetic analysis of the gene for surface layer protein, slpA, from 14 PCR ribotypes of *Clostridium difficile*. J Med Microbiol. 2009;58:69–83. DOI: 10.1099/jmm.0.46204-0

7. Fagan RP, Albesa-Jové D, Qazi O, Svergun DI, Brown KA, Fairweather NF. Structural insights into the molecular organization of the S-layer from *Clostridium difficile*. Mol Microbiol. 2009;71:1308–22. DOI: 10.1111/j.1365-2958.2009.06603.x

8. Stabler RA, He M, Dawson L, Martin M, Valiente E, Corton C, et al. Comparative genome and phenotypic analysis of *Clostridium difficile* 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol. 2009;10:R102. DOI: 10.1186/gb-2009-10-9-r102

9. Barbier F, Mastrantonio P, Delmé M, Brazier J, Kuijper E, Poxton I. European Study Group on *Clostridium difficile* (ESGCD). Prospective study of *Clostridium difficile* infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect. 2007;13:1048–57. DOI: 10.1111/j.1469-0691.2007.01824.x

10. Cheknis AK, Sambol SP, Davidson DM, Nagaro KJ, Mancini MC, Hidalgo-Arroyo GA, et al. Distribution of *Clostridium difficile* strains from a North American, European, and Australian trial of treatment for *C. difficile* infections: 2005–2007. Anaerobe. 2009;15:230–3. DOI: 10.1016/j.anaerobe.2009.09.001

**Introduction of Japanese Encephalitis Virus Genotype I, India**

**To the Editor:** Seasonal outbreaks of fatal acute encephalitis syndrome (AES) occur regularly in several parts of India. Japanese encephalitis virus (JEV) has been the major and consistent cause of these outbreaks in the Gorakhpur region of Uttar Pradesh State, accounting for ≥10%–15% of total AES cases annually (1–3). In India, vaccinations against Japanese encephalitis (JE) are administered in areas where the disease is hyperendemic, including Gorakhpur, and AES cases are regularly investigated to clarify the effects of vaccination. Currently, >2,000 patients with AES are admitted each year to Baba Raghav Das Medical College, Gorakhpur.

JEV is classified into 5 genotypes. Genotype III (GIII) is widely distributed in Asian countries, including Japan, South Korea, the People’s Republic of China, Taiwan, Vietnam, the Philippines, India, Nepal, and Sri Lanka (4). However, during the past decade, JEV GI has been introduced into South Korea, Thailand, and China and has replaced the GIII strains that had been circulating in Japan and Vietnam during the mid-1990s (5). Until 2007, all known JEV strains isolated in India belonged to GIII (2–4,6). The JE-endemic Gorakhpur region recorded a sudden increase in AES cases during September–November 2009. Clinical specimens collected from 694 hospitalized patients were examined for JEV infection by JEV-specific immunoglobulin M capture ELISA (7). Clinical specimens comprising 115 (16.6%) cerebrospinal fluid (CSF) specimens and 114 (16.4%) serum specimens showed recent JE infection among 158 (22.7%) of the case-patients.

All CSF specimens were processed for JEV genome detection by diagnostic reverse transcription–PCR

**LETTERS**

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 2, February 2011
(RT-PCR), which amplified the nucleocapsid-prenmembrane genes (7). Additionally, envelope (E) gene–specific primers designed from Indian JEV isolate GP78 (GenBank accession no. AF075723) were used for E gene amplification.

The diagnostic RT-PCR detected JEV in 66 (9.5%) of 694 CSF specimens (GenBank accession nos. HM156543–HM156569, HM156573–HM156611). Among them, 27 sequences differed from the remaining 39, with only 86.2%–88.7% nt identity. The group of 27 sequences showed 99.2%–100% nt identity with each other and a high of 95.0% nt identity with Japanese GI swine JEV isolate (AB241119). The 39 sequences showed 94.2%–100.0% nt identity with each other and with other Indian GII JEV strains. These findings indicate that both GI and GII JEV strains circulate in the Gorakhpur region.

The E gene sequence was amplified from 4/66 JEV-positive CSF samples (GenBank accession nos. HM156570–HM156572, HM156612). A comparison of E gene nucleotide sequences those of other JEV isolates from the region showed that 1 E gene sequence belonged to GIII and the other 3 to GI (Figure). The 3 GI E gene sequences were most similar (98.6%) with Japanese isolate 95–167/1995/swine (AY377579), followed by 98.5% similarity with Korean isolate K96A07/1996 (FJ938219). The single GIII E gene sequence showed 95.6%–99.8% nt identity with other Indian GIII isolates with the highest similarity (99.8% nt) with the 014178 (EF623987) JEV isolate from the 2001 Uttar Pradesh outbreak.

Analysis of the E gene sequence amplified from 2 JEV isolates, obtained by injecting 29 CSF samples, positive by RT-PCR, into baby hamster kidney cells, showed 100.0% nt identity with sequences directly amplified from respective CSF specimens (3). Phylogenetic analysis of these E gene sequences, along with other 55 GenBank sequences, confirmed that 3 sequences belonged to JEV GI, and 1 belonged to GII (Figure).

The first JE outbreak in the Gorakhpur region was documented during 1978. Since then, JE epidemics have occurred regularly (8). This study demonstrated simultaneous detection and isolation of GI and GII JEV strains from AES case-patients. Documented clinical symptoms among patients infected with the 2 strains were indistinguishable.

![Figure](insert)

**Figure.** Phylogenetic tree constructed by using a 1,381-nt Japanese encephalitis virus (JEV) envelope sequence directly amplified from cerebrospinal fluid specimens collected during the acute phase of illness from hospitalized acute encephalitis syndrome patients, India, September–November 2009. Multiple sequence alignment and phylogenetic analysis were conducted by using ClustalW software (www.ebi.ac.uk/Tools/clustalw2/index.html) and MEGA version 4 (www.megasoftware.net). The phylogenetic tree was constructed by the neighbor-joining method and the maximum composite likelihood model. The robustness of branching patterns was tested by 1,000 bootstrap pseudo replications. Sequences obtained in this study are indicated in boldface. Genotypes are indicated on the right. Viruses were identified by using the nomenclature of accession number–strain name–country of origin/year of isolation. Bootstrap values are indicated above the major branch. The tree was rooted within the Japanese encephalitis serogoup by using Murray Valley encephalitis virus (AF161266) and 55 JEV sequences from GenBank were used in the analysis. Scale bar indicates nucleotide substitutions per site.
GI JEV isolates from India share close genetic relationship with GI strains from Japan and Korea. In India, JEV neutralizing antibodies have been detected in 179 (34.8%) of 514 birds, including pond herons and cattle egrets, indicating a possible role in virus maintenance (9). Large perennial lakes, swamps, and rice fields provide a wintering and staging ground for several migratory waterfowl; such areas also favor breeding and survival of mosquitoes (10). Considering these conditions, GI JEV may have been introduced into India through migratory birds, as it has in other Asian countries (5). However, the exact mode of introduction of GI JEV into India is not known, and further studies are needed to determine the role of migratory birds in JE transmission.

This study suggests the recent introduction of JEV GI strain in India. Simultaneous detection of GI and GIII strains indicates their co-circulation and association with human infections in Gorakhpur region. Because the live attenuated JE vaccine used in India is derived from GIII strain SA14–14–2, the efficacy of the vaccine to protect against GI JEV must be carefully evaluated. Thus, the genetic and antigenic variation among JEV strains circulating in India should be monitored to determine effects on JE epidemiology and ongoing vaccination efforts. Additionally, the expansion of GI JEV into other parts of India should be continuously tracked.

Acknowledgment

We thank the Directorate of Health Services, Government of Uttar Pradesh, India, for support. We also are grateful to K.P. Kushwaha and A.K. Thacker for their efforts in clinical diagnosis and to V. Shankararaman, V.M. Ayachit, V. Sonawane, S. Mahamuni, V. Phokmare, and staff members from the National Institute of Virology Unit, Gorakhpur, for technical support.

This study was supported by the Indian Council of Medical Research, Ministry of Health and Family Welfare, Government of India.

Pradip V. Fulmali, Gajanand N. Sakpal, Sulabha Athawale, Milind M. Gore, Akhilesh C. Mishra, and Vijay P. Bondre

Author affiliations: National Institute of Virology, Pune, India (P. V. Fulmali, G.N. Sakpal, S. Athawale, A.C. Mishra, V.P. Bondre); and National Institute of Virology, Gorakhpur, India (M.M. Gore)

DOI: 10.3201/eid1702.100815

References

1. Saxena V, Dhole TN. Preventive strategies for frequent outbreaks of Japanese encephalitis in northern India. J Biosci. 2008;33:505–14. DOI: 10.1007/s12038-008-0069-9
2. Saxena SK, Mishra N, Saxena R, Singh M, Mathur A. Trend of Japanese encephalitis in north India: evidence from thirty-eight acute encephalitis cases and appraisal of niceties. J Infect Dev Ctries. 2009;30:517–30.
3. Sakpal GN, Bondre VP, Fulmali PV, Patil P, Gopalkrishna V, Dadhania V, et al. Enteroviruses in patients with acute encephalitis, Uttar Pradesh, India. Emerg Infect Dis. 2009;15:295–8. DOI: 10.3201/ eid1502.080865
4. MacKenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med. 2004;10(Suppl):S98–109. DOI: 10.1038/nm1144
5. Huang JH, Lin TH, Teng HJ, Su CL, Tsai KH, Lu LC, et al. Molecular epidemiology of Japanese encephalitis virus, Taiwan. Emerg Infect Dis. 2010;16:876–8.
6. Uchil PD, Satchidanandam V. Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering, and multiple introductions of the virus into the Indian subcontinent. Am J Trop Med Hyg. 2001;65:242–51.
7. Sakpal GN, Walragkar NS, Ayachit VM, Bondre VP, Gore MM. Detection and isolation of Japanese encephalitis virus from blood clots collected during the acute phase of infection. Am J Trop Med Hyg. 2007;77:1139–45.
8. Mathur A, Chaturvedi UC, Tandon HO, Agrawal AK, Mathur GP, et al. Japanese encephalitis epidemic in Uttar Pradesh, India during 1978. Indian J Med Res. 1982;75:161–9.
9. Rodrigues FM, Guttikar SN, Pinto BD. Prevalence of antibodies to Japanese encephalitis and West Nile viruses among wild birds in the Krishna-Godavari Delta, Andhra Pradesh, India. Trans R Soc Trop Med Hyg. 1981;75:258–62. DOI: 10.1016/0035-9203(81)90330-8
10. Tripathy SC. Can Bakhira bird sanctuary safeguard the purple moorhens? Curr Sci. 2004;86:367–8.

Dengue Virus Serotype 3 Subtype III, Zhejiang Province, China

To the Editor: Beginning in July 2009, physicians in the city of Yiwu, Zhejiang Province, People’s Republic of China, noted an outbreak of illness characterized by rash, headache, subjective fever, itching, anorexia, and arthritis. We present the results of the investigation of this outbreak, which was caused by dengue virus (DENV) serotype 3 (DENV-3) subtype III.

DENV-3 subtype III has been continuously circulating in the Indian subcontinent since the 1960s. The virus was first isolated from East Africa in 1985 in Mozambique and subsequently in Kenya (1991) and Somalia (1993) (1,2). Although dengue has occurred frequently in southern China, including Guangdong, Guangxi, Hainan, Fujian, and Zhejiang Provinces and in Taiwan (3–6), to our knowledge, DENV-3 subtype III has not been reported in China.